- Pembrolitzumab in the treatment of NSCLC2017 | Publication without faculty affiliation
- Strategies for current NSCLC treatment2020 | Publication without faculty affiliation
- Osimertinib and its role in first-line NSCLC treatment2020 | Publication without faculty affiliation
- What approach to ALK-positive NSCLC?2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- First-line immunotherapy in NSCLC - what brought 20182018 | Faculty of Medicine in Pilsen
- Personalized cancer treatment of patients with advanced-stage NSCLC2015 | Faculty of Medicine in Pilsen, Faculty of Science
- EGFR mutations in patients with advanced NSCLC2012 | Faculty of Medicine in Pilsen
- KRAS (G12S) mutation in a patient with NSCLC treated with erlotinib – a case report2013 | Faculty of Medicine in Pilsen
- The role of durvalumab in the treatment of stage III NSCLC2020 | First Faculty of Medicine
- Case report of a patient with generalized NSCLC with high PD-L1 expression treated with pembrolizumab2020 | Publication without faculty affiliation
- The current standard of NSCLC pathological examination in the Czech Republic2022 | Faculty of Medicine in Hradec Králové
- Complete response to pembrolizumab in a patient with stage IV NSCLC (non-small cell lung cancer)2020 | First Faculty of Medicine
- Erlotinib in treatment of NSCLC focusing on patients without EGFR mutation and on combination of erlotinib with bevacizumab2017 | Faculty of Medicine in Pilsen
- Erlotinib in Treatment of NSCLC (Focusing on Patients without EGFR Mutation and on Combination of Erlotinib with Bevacizumab)2017 | Faculty of Medicine in Pilsen
- Ground-breaking ADAURA trial - osimertinib as adjuvant therapy of EGFR-mutated NSCLC2022 | First Faculty of Medicine
- NSCLC (Non-Small Cell Lung Cancer) and kidney tumor in the elderly patient with response to chemoimmunotherapy2021 | First Faculty of Medicine
- Commenting on the study: efficacy and safety of maintenance treatment with pemetrexed in patients with advanced NSCLC nonskvamózním after induction therapy with pemetrexed plus cisplatin - comparison studies JMBD and PARAMOUNT2014 | Publication without faculty affiliation
- Nivolumab in treatment of NSCLC2016 | Publication without faculty affiliation
- Cemiplimab: monotherapy and combination therapy of NSCLC - analysis of locally advanced disease2023 | First Faculty of Medicine
- Efficiency and safety of pemetrexed and cisplatin therapy in the adenocarcinoma and large cell cancer types of advanced non-small cell lung cancer (NSCLC)2012 | Publication without faculty affiliation
- Monitoring of the expensive pneumooncological tratment of the advanced non-small cell lung cancer (NSCLC) in the 1st line in the TULUNG registry in the Czech Republic2012 | First Faculty of Medicine, Third Faculty of Medicine
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Second Faculty of Medicine
- The use of tumor markers in predicting reccurence of non-small cell lung cancer (NSCLC) after radical surgery2007 | Central Library of Charles University
- Treatment of locally advanced NSCLC in the context of current guidelines2021 | Publication without faculty affiliation
- Longer survival in patients with NSCLC thanks to the combination of chemotherapy, immunotherapy and targeted therapy in the first line palliative treatment - results of the IMpower150 study2020 | Third Faculty of Medicine
- Diagnostic and therapeutic guidelines for stage III non-small-cell lung cancer2016 | Faculty of Medicine in Pilsen
- New options of expensive pneumo-oncological therapy for advanced non-small-cell lung carcinoma (NSCLC) in the first line based on morphological and molecular genetic diagnosis in the Czech Republic2012 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Analysis of advancer NSCLC patients with prolonged progression-free survival after EGFR tyrosine kinase therapy2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Organisation of care in NSCLC patients in Czech republicPublication without faculty affiliation
- Rare case of choroidal metastasis in ALK-positive NSCLC that responds to crizotinib2019 | First Faculty of Medicine